Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD

Trial Profile

Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Flibanserin (Primary)
  • Indications Decreased libido; Female sexual dysfunction
  • Focus Adverse reactions; Registrational
  • Acronyms SUNFLOWER
  • Sponsors Boehringer Ingelheim; Sprout Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2015 Results published in the Annals of Pharmacotherapy
    • 20 Dec 2015 According to the pooled results published in Annals of Pharmacotherapy, this trial is an extension study of BEGONIA trial (a multicentre, double blinded, placebo controlled, 24-week trial conducted in North America).
    • 12 Jun 2014 Status changed from completed to discontinued,as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top